Featured Speakers

• 

  Kiran PatelVP, Medicine Development Leader, Oncology R & D GSK

• 

  Michael GottesmanChief, Laboratory of Cell Biology, and Head, Multidrug Resistance Section Center for Cancer Research NCI, NIH

• 

  Michael ZindaExecutive Director AstraZeneca

• 

  Pasi JanneAssociate Professor Harvard Medical School

Create therapies that overcome cancer drug resistance

After years of research and billions of dollars worth of investment cancer therapies are still failing. The major reason? Resistance.

Understanding tumor evolution and mechanisms of drug resistance is crucial for developing successful therapies. Therapies that delay the onset of resistance will have increased durability, will add more value to your pipeline and will be of greater benefit to patients.

Targeting Cancer Drug Resistance is about the approaches drug developers are taking to tackle resistance in the clinic. All to enable you to develop therapies that will overcome resistance, impact the market for longer and increase patient survival.

This meeting will arm you with information to increase the durability of drugs currently in your pipeline, as well as rationally guide future therapeutic approaches. 

Hear the pioneering discoveries in tumor biology that reveal how cancer can evade current treatments, how cancer adapts, evolves and develops. Learn the translational approaches drug developers are taking to turn these discoveries into successful therapies. Apply what you’ve learnt to your own pipeline to accelerate progression of your therapies through the clinic.

This meeting provides a comprehensive investigation into all of the mechanisms for overcoming cancer drug resistance, allowing you to develop more successful, commercially viable therapies. 

Attend Targeting Cancer Drug Resistance to:

• Identify new mechanisms of resistance and gain a greater understanding of tumor biology. Hear groundbreaking talks from experts at The National Cancer Institute, MD Anderson Cancer Center and Harvard Medical School. Use this information to shape current and future drug development
• Discover how experts at AstraZeneca, Gilead and Genentech are developing new therapies that overcome resistance. Use these successful case studies to guide your own strategic approach and maximize your chances of success.
• Accelerate combination therapies from bench to bedside to benefit patients faster. Hear how Zalicus are testing for combination quickly, effectively and rationally through efficient screening processes
• Discover the different approaches Verastem, OncoMed, Regeneron and ImmunoCellular Therapeutics are taking to target cancer stem cells in the clinic. Learn how these innovative approaches are crucial for tackling resistance and would be an asset to your drug development pipeline
• Get involved in the round table discussions and debate with both academics and experts from industry that are passionate about accelerating progression in the cancer drug resistance field. Benefit from a spectrum of experience that will give you a comprehensive view of the entire field 

Who Should Attend?

Drug developers and research professionals who are dedicated to overcoming resistance through evolving their knowledge of resistance mechanisms and applying this knowledge to developing improved cancer therapies.

The following have already expressed an interest in the meeting

• Head of Oncology R&D
• Director of Oncology
• Research scientist Oncology
• Clinical Trial Head Oncology
• Academia